X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KVA12123, VISTA inhibitor, in combination with Keytruda. Currently, it is being evaluated in the Phase III clinical trial studies for the treatment of neoplasms including Lung Cancer.
Lead Product(s): KVA12123,Pembrolizumab
Therapeutic Area: Oncology Product Name: KVA12123
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2024
Details:
KVA12123 is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope. It is under phase 1/2 clinical development for the treatment of advanced solid tumors.
Lead Product(s): KVA12123
Therapeutic Area: Oncology Product Name: KVA12123
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2024
Details:
KVA12123 is expected to be a differentiated VISTA blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment, which is being investigated in combination with pembrolizumab in patients with advanced solid tumors.
Lead Product(s): KVA12123,Pembrolizumab
Therapeutic Area: Oncology Product Name: KVA12123
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2023
Details:
KVA12123 is expected to be a differentiated VISTA blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment. It is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope.
Lead Product(s): KVA12123,Pembrolizumab
Therapeutic Area: Oncology Product Name: KVA12123
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2023
Details:
The agreement aims to evaluate VISTA expression as a potential biomarker in cancer patients from Kineta’s ongoing Phase 1/2 clinical trial evaluating KVA12123, the company’s VISTA blocking immunotherapy, alone and in combination with pembrolizumab.
Lead Product(s): KVA12123,Pembrolizumab
Therapeutic Area: Oncology Product Name: KVA12123
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Fred Hutchinson Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 18, 2023
Details:
The collaboration is focused on the discovery and development of two novel Yumanity pipeline programs for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTLD).
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration June 29, 2023
Details:
KVA12123 is expected to be a differentiated VISTA blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment. It is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope.
Lead Product(s): KVA12123,Pembrolizumab
Therapeutic Area: Oncology Product Name: KVA12123
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2023
Details:
KVA12123 is expected to be a differentiated VISTA blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment. It is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope.
Lead Product(s): KVA12123
Therapeutic Area: Oncology Product Name: KVA12123
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Yumanity Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 19, 2022
Details:
KVA12123 is expected to be a differentiated VISTA blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment. It is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope.
Lead Product(s): KVA12123,Pembrolizumab
Therapeutic Area: Oncology Product Name: KVA12123
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 19, 2022
Details:
KVA12123 is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope and at physiologic and acidic pH levels.
Lead Product(s): KVA12123,Pembrolizumab
Therapeutic Area: Oncology Product Name: KVA12123
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
